Highlights Camurus AB

Equities

CAMX

SE0007692850

Market Closed - Nasdaq Stockholm Other stock markets 04:29:30 08/05/2024 pm IST			5-day change	1st Jan Change
535 ^SEK	+7.82%		+7.39%	-0.56%

08/05	Camurus AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
17/04	Certain Shares of Camurus AB are subject to a Lock-Up Agreement Ending on 17-APR-2024.	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Camurus AB Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
Camurus AB Announces FDA Acceptance of NDA Submission for Oclaiz? for Treatment of Acromegaly	05/03	CI
Camurus AB Reports Earnings Results for the Full Year Ended December 31, 2023	15/02	CI
Camurus AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	15/02	CI
Camurus AB Provides Earnings Guidance for the Full Year 2024	15/02	CI
Camurus AB Completes Enrollment in the POSITANO Study of CAM2029 in Patients with Polycystic Liver Disease	08/02	CI
Camurus AB Submits New Drug Application to the US FDA for Oclaiz for Treatment of Acromegaly	21/12	CI
Camurus to Trade on Nasdaq Stockholm's Large Cap Segment	20/12	MT
Camurus AB Announces Completed Enrollment in the Phase 3 SORENTO Study of CAM2029 in Patients with Neuroendocrine Tumors	14/12	CI
Camurus AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11	CI
Camurus AB Raises Earnings Guidance for the Year 2023	23/23/23	CI
Camurus Announces US Launch of Brixadi for the Treatment of Moderate to Severe Opioid Use Disorder by Braeburn	05/23/05	CI
Camurus AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	18/23/18	CI
Camurus AB Provides Earnings Outlook for the Year 2023	18/23/18	CI
Camurus Announces New Phase 3 Data Recalling Long-Term Safety and Efficacy of Octreotide Sc Depot in Patients with Acromegaly	17/23/17	CI
Camurus Announces Positive Topline Results from A 24-Week Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial, Acromegaly	20/23/20	CI
Camurus Announces FDA Approval of Brixadi for the Treatment of Moderate to Severe Opioid Use Disorder	24/23/24	CI
Camurus AB Reports Earnings Results for the First Quarter Ended March 31, 2023	10/23/10	CI
Camurus AB Provides Earnings Guidance for the Year 2023	10/23/10	CI
Camurus AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	14/23/14	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Camurus AB

Equities

CAMX

SE0007692850

Highlights

Filters